Mebcavir 200 mg Capsule is the first oral antiviral medication approved to treat mild to moderate COVID-19 in adults. It works by preventing the virus from multiplying, thereby reducing the viral load and severity of the disease. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021.

Mebcavir 200 mg Capsule is specifically indicated for patients with mild to moderate COVID-19 symptoms who are at high risk of developing severe illness. Risk factors include obesity, age over 60, diabetes, and heart disease. It is not intended for use in patients who require immediate hospitalization due to COVID-19. The U.S. Food and Drug Administration (FDA) and the UK regulatory agency have also granted emergency use authorization for this medication.

Mebcavir 200 mg Capsule should be taken orally for no longer than 5 consecutive days. It is crucial to complete the full 5-day course, even if you start feeling better, to ensure the effectiveness of the treatment. Common side effects may include dizziness, headache, diarrhea, and nausea. If you experience any of these side effects, consult your doctor, who may provide supportive treatment or suggest ways to minimize them.

Before starting Mebcavir 200 mg Capsule, inform your doctor of any pre-existing medical conditions and provide a list of all medications you are currently taking to ensure it is safe for you. The use of Mebcavir 200mg Capsule is not recommended during pregnancy. Pregnant and breastfeeding women should consult their doctors before taking this medication.